ReNewVax is proud to participate in BioInfect 2024, a major conference set to commemorate the ten-year anniversary of the influential O’Neill Review on AMR. Hosted at The Spine in Liverpool’s Knowledge Quarter, the event will bring together key figures from academia and industry to discuss breakthroughs in combatting AMR and fostering collaborative innovation within the sector.
Lord Jim O’Neill, the author of the groundbreaking 2014 O’Neill Review on AMR, will be a keynote speaker at BioInfect 2024, along with Liverpool City Region Mayor Steve Rotheram and Professor Janet Hemingway, former director of Liverpool School of Tropical Medicine and Director of the Infection Innovation Consortium: iiCON.
The conference, organized by the non-profit life sciences membership organization Bionow, aims to recognize the strides made in the global fight against AMR and explore opportunities for collaborative innovation. In addition, it will celebrate the launch of England’s Health and Life Sciences Investment Zone in the Liverpool City Region.
RenewVax Ltd, are proud to be an event partner alongside organizations such as Appleyard Lees, iiCON, Evotec, and Bruntwood SciTech, acknowledges the importance of collective efforts to address the critical issue of AMR. The World Health Organization (WHO) attributes almost five million deaths annually to bacterial infections, with an estimated global economic cost of $100 trillion by 2050.
Professor Janet Hemingway, Founding Director of iiCON, emphasized the urgency of addressing AMR as the critical global health issue of our time. She stressed the need for collaboration among experts from various fields to develop new approaches and ensure that industry, research, and policy are aligned for the development and implementation of new treatments and solutions.
Dr. Neil Murray, CEO of ReNewVax Ltd, highlighted the UK’s leading role in the fight against AMR, as demonstrated by the O’Neill Review. He emphasized the significance of the infectious disease capability in the Liverpool City Region and the wider North West in continuing to lead the fight against this defining healthcare challenge.
With the threat of AMR designated as one of the top 10 global public health threats by the WHO, BioInfect 2024 provides a valuable platform to stimulate debate, encourage collaboration, and address the challenges posed by antimicrobial resistance. For more information on the conference, please visit BioInfect 2024.